Physician profile
Mark Andreozzi
NPI 1487701975
$14,778.02
in general payments reported to CMS, 2019-2025
34 companies · $2,767 in 2025
The $2,767 reported for 2025 was more than what 93% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,187 · 2020: $796 · 2021: $1,999 · 2022: $2,623 · 2023: $2,503 · 2024: $1,902 · 2025: $2,767.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,172.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,172.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $3,749.91 | 2019-2025 | Airsupra, Tezspire, Breztri |
| Glaxosmithkline, LLC. | $2,308.62 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $2,005.90 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,467.60 | 2019-2025 | Dupixent |
| Optinose US, INC. | $656.98 | 2019-2025 | |
| Abbvie INC. | $523.97 | 2021-2025 | Ubrelvy |
| Pfizer INC. | $505.07 | 2023-2025 | |
| Genentech USA, INC. | $480.31 | 2019-2025 | Xolair |
| Novartis Pharmaceuticals Corporation | $322.81 | 2019-2025 | |
| Kaleo, INC. | $275.88 | 2019-2024 | Auvi-Q |
| Stryker Corporation | $269.59 | 2019-2025 | Xpress Loprofile |
| Intersect Ent, INC. | $246.21 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $205.74 | 2019-2022 | |
| Acclarent, INC | $175.36 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $173.57 | 2019-2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company Ltd. | $168.74 | 2022 | |
| Inspire Medical Systems, INC. | $168.67 | 2025 | Inspire |
| Alk-Abello, INC | $132.43 | 2019-2023 | Ragwitek, Grastek, Odactra |
| Biohaven Pharmaceuticals, INC. | $132.42 | 2021 | |
| Amgen INC. | $130.68 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $124.39 | 2023 | |
| Puma Biotechnology, INC. | $104.39 | 2021 | |
| Smith+Nephew, INC. | $82.95 | 2019-2020 | |
| Hikma Pharmaceuticals USA | $67.39 | 2023-2024 | Ryaltris |
| Ars Pharmaceuticals Operations, INC. | $66.95 | 2025 | Neffy |
| Aerin Medical INC. | $47.69 | 2019-2022 | |
| Medtronic, INC. | $31.37 | 2021-2022 | |
| Watermark Medical, INC. | $30.21 | 2024 | |
| Pharming Healthcare, INC. | $28.03 | 2023 | Ruconest |
| Paratek Pharmaceuticals, INC. | $25.99 | 2025 | Xhance |
| Leo Pharma INC. | $18.85 | 2022 | |
| Aimmune Therapeutics, INC. | $18.32 | 2022 | |
| Allergan, INC. | $15.55 | 2020 | |
| Omeros Corporation | $15.48 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Andreozzi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.